Fig. 1From: D-galactose supplementation in individuals with PMM2-CDG: results of a multicenter, open label, prospective pilot clinical trialResponse to Galactose treatment. Response to escalating dose of oral D-galactose supplementation in nine patients carrying different biallelic pathogenic variants in PMM2 on the NPCRS score (a)–(d) and on glycosylation (e), (f)Back to article page